NVP-AUY922, a novel HSP90 inhibitor, inhibits the progression of malignant pheochromocytoma in vitro and in vivo

PURPOSE: Malignant pheochromocytoma (PCC) is a rare tumor with a very poor prognosis and no effective treatments. The aim of this study was to assess the efficacy of a novel second-generation synthetic heat-shock protein 90 (HSP90) inhibitor, NVP-AUY922, to treat malignant PCC in vitro and in vivo....

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Onco Targets Ther
Asıl Yazarlar: Lian, Jianpo, Lin, Dengqiang, Xie, Xing, Xu, Yunze, Xu, Lieyu, Meng, Li, Zhu, Yu
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove Medical Press 2017
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5403128/
https://ncbi.nlm.nih.gov/pubmed/28458565
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S130236
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller